Why phage companies aren’t raising $400M rounds… yet | Paul Garofolo — Podovirus podcast
1 hr 02 min

Why phage companies aren’t raising $400M rounds… yet | Paul Garofolo

The conversation

Episode notes

Paul Garofolo, who describes founding Locus Biosciences in 2015, explains how developing engineered phage drugs changed his thinking about clinical trials and investment. Listeners learn why he sees inexpensive entry into trials as a potential trap, and how patient selection, drug exposure and convincing data shape the field’s prospects.

Garofolo reports 94% cocktail sensitivity across roughly 200 phase zero patients and subsequent early trial datasets, illustrating how advance sampling can test whether laboratory host coverage carries into trials.

Garofolo argues that early trials should establish drug exposure and tolerability before advancing, because even an effective drug could fail when its quantity or dosing schedule misses the target.

Garofolo suggests phage manufacturing could support treatment prices around $1,500–$2,500, potentially enabling broader hospital use, while stressing that companies still need to learn how to harness that production advantage.

Episode timeline

  • 0:00 Introduction and Locus’s path from CRISPR to phage
  • 10:16 Automated cocktail design and phase zero trial preparation
  • 19:25 How trial design and weak data affect investment
  • 28:04 Choosing cocktails for difficult infection environments
  • 42:21 Microbiome lessons: removing bacteria before adding more
  • 49:53 Five- and fifteen-year plans, pricing and prevention

Learn more

Transcript

AI-transcribed and edited for readability. May contain errors or omissions; check the recording for exact wording.

Select a word or timestamp to listen. Use arrow keys to move between words.

  1. Joe Campbell

    We should get started. It's great to have Paul Garofolo here today for another segment of our podcast. And we're excited to talk to Paul because he has an interesting perspective on phage therapy, and we like to get those interesting perspectives and have interesting conversations. So we'll start out, maybe Paul, by having you introduce yourself. Tell us a little bit about your background before phage and how you got into phage.

  2. Paul Garofolo

    Sure, I am, 30, almost 35 years in biopharma at this point. I, began my career as a management consultant with Ernst & Young and pretty much immediately got assigned to Genentech. And have been unable to escape the magnetic pull of biopharma since. I spent probably ten years, doing consulting out on the West Coast, before I eventually joined the executive team at Valeant Pharmaceuticals.

    I was the CIO for that group for some years and as well had a short stint as global head of manufacturing and supply. Left there to join the executive team, for Patheon Pharmaceuticals in North Carolina, was the chief technology officer for them, but also ran worldwide operations for all of what they called their PDS division, or their pharmaceutical development services. So essentially all clinical trial material manufacturing and support.

    And, it was at the end of that run, we had a really nice couple of exits there, and it was the end of that one that I decided I'd like to start a company. I had been an executive-in-residence, helping to support the NC State, Poole College of Management, and was able to actually pick up, a little thing called CRISPR-Cas3 out of one of the students’, inventions that had been brought into an entrepreneurship class.

    So that was maybe the better part of ten years ago and have been the CEO for Locus Biosciences since forming the company in 2015. So I guess you could say, I'm a management consultant with sort of an IT background, that ventured into both manufacturing and drug development for pharma before, taking a swing at a startup. So it's been an interesting ride.

  3. Jessica Sacher

    Awesome.

  4. Joe Campbell

    And maybe you can tell us a little bit about, I mean, you mentioned that you got involved with CRISPR assets, but what made you think that it was a good time to get into the phage space?

  5. Paul Garofolo

    Well, actually, it's interesting. So our origin story for the creation of Locus is actually more of a CRISPR story than a phage story. When we started the company, we actually started it as a CRISPR, biotech.

    And we had thought that we were first to file on, CRISPR-Cas3, and we knew we had a payload. What we didn't have was a delivery system. And so we actually started the company with three different pieces of technology: one was from Duke, one was from UNC, one was from NC State. But it was cell-penetrating peptides, some nanotechnology and phage.

    And so the idea of the first year of the company was to really figure out which vector was going to work for the CRISPR-Cas3 system, really. And within like nine months to twelve months, we figured out phage was probably the preferable vector, and within two years of starting the company, we had a data set that was being compiled around our lead E. coli asset that was actually…

    It showed the greatest versatility and started to pick up support from the FDA for some favorable drug development pathway opportunities. And so by the time, we were probably year two or three into the company, we were pretty much 100% phage. So yeah, our story to get to phage was a little bit, around some outside buoys. As it turns out, CRISPR-Cas3 is huge.

    It's just a large complex of enzymatic parts and pieces, if you will. And cell-penetrating peptides couldn't really hold it all, so they got eliminated pretty quick. The nanotech actually went pretty far, but nanotechnology does not have the same benefit as phage in that it actually can essentially, get into human cells. And so phage had this wonderful attribute for antibacterial therapeutics anyway, of not being able to infect human cells.

    And so therefore created this great safety balance. And so just by virtue of how much you could insert into a phage, as well as what we anticipated in the early days was pretty favorable regulatory support, we jumped in headfirst after, I guess, after our Series A funding round came through, so that was about two and a half to three years after we started the company.

  6. Jessica Sacher

    That's super interesting. I didn't know it was a phage delivery story. That's what we're diving into in the Bollyky lab right now is phage as delivery vectors. And kinda trying to, you know, actually look at even for human cells now, which would be the dark side. But yeah, like, how big is Cas3 roughly? And do you feel like, you'll in the future be going down more phages to deliver other stuff?

    Or stick with the payload? Like, have you found that the payload is kind of like the more important aspect of the drug, or the delivery vector?

  7. Paul Garofolo

    So we're well beyond CRISPR-Cas3 now.

  8. Jessica Sacher

    Okay, ah,

  9. Paul Garofolo

    We just had an IND approved last month for, or I guess it was this month, for Crohn's disease. And that is actually, a set of payloads that actually can work exogenously, which is what we were looking for gut delivery, to see if we couldn't target and basically eat through whatever is holding these adherent-invasive E. coli in place in the intestinal tract. And so, we actually, I would say, to answer your first question, Cas3, along with Cascade, which is needed to be able to fully express the enzyme, is probably about seventy five hundred base pairs large.

  10. Jessica Sacher

    Got it.

    Okay.

  11. Paul Garofolo

    It probably can range up even further for some systems. They probably get up into 9,000, even 9,500. And I think the smallest we ever messed around with was maybe sixty three hundred base pairs.

  12. Jessica Sacher

    Okay.

  13. Paul Garofolo

    So large, but very large, and multifactorial, by the way. So it's not like it's one little peptide. It's a bunch of component parts and pieces that need to be reassembled in, presumably, the exact right shall we say stoichiometry. And then you get this, you know, wonderful added killing effect. And so, we certainly didn't start with low-hanging fruit when we were starting to figure out, um, engineered phage, and I think we're exclusively an engineered phage company. We believe that engineering payloads into the phage vectors is the key to breaking out the sort of future of medicine in this modality. And, um, we do our best to not impact the lytic killing capability of the phage cocktails that we deploy.

    So we really try to harness and lever a duplicity of MOAs to be able to get to comparability in killing against antibiotics. And that, I think, is well to be proven out, in humans, but I think today we dosed patient 188 out of 288. So we're pretty close to flipping what should be the largest data set of its kind.

    In the phage field, we'll see what the data reads out at.

  14. Jessica Sacher

    Yeah, wow, Joe, do you have something? Cause I got millions of questions.

  15. Joe Campbell

    Yeah, and just, you know, our usual. Once we get you to how you started with phage, sort of, you know, what have you learned? I mean, you've learned a lot, I know, but you know, what are the big things you've learned since the time you started using phage to now?

  16. Paul Garofolo

    So what I think is maybe a little interesting about our origin story, and you know this background, Joe, and maybe most people in the field do, too. But so Jessica, we came out of NC State, really hot and heavy on CRISPR-Cas3 systems, and then, pretty quickly engaged in fairly large strategic partnership discussions. Johnson & Johnson was the primary anchor, but there were some others.

    And it wasn't until we acquired EpiBiome, who had been working really for years on high-throughput screening, liquid handlers, as well as machine learning, for various types of engineering to phage. It wasn't until we put the two companies together that we actually broke out and got that Janssen deal, which I think was sort of industry-setting at the time. Eight hundred million dollar deal.

    By the time the whole thing came crumbling down, we were able to get about eighty five million of Funding from Johnson & Johnson on, really four key indications across both Pseudomonas and Staph. So it's been fantastic being able to sort of leapfrog off of that. But I would say, Joe, that the answer to the question lies in that technology move. So we, I think, like most, had assumed that you'd discover great phage down at your local sewer treatment plant, fish them out,

    basically characterize them, stick them in a cocktail and go. What I think the guys at EpiBiome did, you know, Aeron Hammack and Nick Conley, pretty ahead of their time, was to, basically, move to an automated robotic platform to discover phage en masse, characterize en masse. And then use essentially early-stage AI to figure out how to put those things together. Looking at things like burst size, receptors, I mean, you name it, and trying to figure out:

    How do you put together a cocktail of phage that's comparable or superior to an antibiotic? And, to us, that's really what we believe. We believe that… Discover thousands of target phage against a target species or genus, characterize those en masse, figure out which ones are ripe for engineering, which could be ones others easily eliminate, right? Ones that maybe don't have the greatest host ranges, but have some property we really want, like a receptor overlap or something along those lines. Engineer a payload into it to get its killing efficacy above its natural wild-type counterpart and put it together into a fixed cocktail. And if we're right about it, you end up with a drug that ends up in a single vial, could be lyophilized down into a powder and brought to a pill, so that you can eventually get to a pill-to-pill replacement for antibiotics, which would arguably change the world, right?

    From broad-spectrum pathogenic treatment to precision medicine, which is exciting, I think.

  17. Jessica Sacher

    Hm. Yeah, It's always been fascinating to see. I feel like Locus has done a lot of things. I think a lot of people say this about Locus, that you're doing things in a very practical way. And like, also things that you wouldn't think that people would innovate on. Like, I remember the phase zero trial that you guys were talking about at conferences years back, probably Nick talking about that.

    About how you went out and figured out, like, in advance of the trial itself, which are the patients? Can we actually get enough patients with this profile that, like, our drug, hits? and I'm probably not fully understanding, like the ins and outs of it. But I just remember, like, I always remember that, like, wait, we always think about phase one, two, three, and why not before one?

    And, like, so has that panned out well and like, led to the fact that you're able to kind of move towards successful trials? Do you think? I've always wanted to ask that.

  18. Paul Garofolo

    Yeah, well, I think we're firm believers in phase zeros. It's expensive, usually people can't afford them, but you essentially are trying to both validate the target, hunt for a biomarker that you can use for enrollment, but also vet your facilities and make sure that your target patient population exists before you go into the larger, more expensive trial. You do not need FDA approval to do a phase zero. You do need FDA approval to do a phase one. So I would say 60 to maybe even upwards of 80% of the sites that we used in the phase zero pulled through to the phase one. In the translation of host range against our cocktail, I'm assuming you guys know all these, words. If I lose you anywhere, feel free to stop me.

  19. Jessica Sacher

    All good.

  20. Paul Garofolo

    So we were looking at, I think, 94%, host range coverage, or sensitivity to the cocktail that translated across about a 200-patient phase zero data set. So far, the data that we can report, in the unblinded PK/PD uplift portion of the trial, alongside actually the phase 1b that we also did, they were also both 94% sensitivity. So it had translated from robots to phase zero to phase one to PK/PD uplift. And then we'll see when we unblind the phase two what the numbers look like, but we assume we will get that same host range and that, that's part of it. So, I think maybe one thing we think about is, are all of the phage that you're gonna find for a particular bacteria around the world the same?

    Like, are those actually the same? Are those, maybe different by geographic region? Are there bacterial strain differences that would enable the phage to evolve differently? And I think what we're beginning to lean into is yes, that it is likely there are some geographic differences. And so, is the United States even large enough that you might see differences from coast to coast? We don't 100% know the answer to that, but we suspect, yes.

    And so, maybe tying a few things back together, you know, to be able to hunt for 10,000 phage, characterize them, put them together in a cloud, figure out which ones go best together to get to four or five or six of them that go into a fixed cocktail, to us is critical, to being able to make sure you can translate. And then getting out there in the field and then going to physical locations and getting some potential patient samples, spraying those down with drug product, making sure you have translatability.

    I mean, that's just good trialist homework to make sure you can be successful. There's nothing more deadly to a biotech company than planning to have a trial take two years and it takes five. And especially in the phage arena, it's such a low cost, a low, like, literal financial like floor to be able to get into the industry. I mean, you're, I think a lot of people have had massive difficulties once they hit the clinic.

    It's expensive. It's very hard.

  21. Jessica Sacher

    What do you mean by a low financial floor for our phage research scientist audience? I’m curious about the business side.

  22. Paul Garofolo

    Yeah, I mean, I think, I mean this, Joe and I have talked about this in the past. But, you know, I guess, yeah. I'm not a huge fan of the Cystic Fibrosis Foundation, approach of sort of three to seven million dollars to go conduct a five to ten patient single-facility or dual-facility trial.

    I think that Pseudomonas data that's come in the last, shall we say, four or five years, has been a massive momentum killer for our space. So in other industries or sectors, I would say, let's say you're working in immunology, you're not getting into the clinic for 3 million dollars, you're not sniffing the clinic for 3 million dollars. The sort of normal path to get into the clinic, is, I think, just more advantageous in phage because of the safety profile.

    And so you don't need as much capital raised to get a theoretical drug into a trial. And that, you know, having been in the space for over 30 years, this is where most of us fail is the clinic. It's expensive, it's difficult. You may have the best drug in the world, but if you didn't set up your protocol right, and you don't understand your target patients, and you don't have the right KOLs, and you don't have the right sites, you may never enroll, or if you do enroll, you enroll the wrong patients, and you get bad data and you don't get a second chance.

    So that's to me, I think a huge, huge headwind in the industry is the one that everybody thinks is a tailwind, which is the low financial barrier to get yourself from an academic lab into a clinical trial setting. And I think I don't know of any data that's helped the industry break out And it's… that part is one of the largest challenges in our space. Because why can't we attract 400 million rounds?

    That's a good question, right? ’Cause other people are attracting 400 million rounds, so why aren't we attracting 400 million rounds with our safety profile? How come we're not attracting 400 million rounds? I think it's because there's been some damage done, by essentially the creation of data sets that, aren't great. They show promise, not for a private equity firm or for a major venture capitalist, but they show promise.

    And that I think is something we really, really hope at Locus, that we blaze a new path and that it opens up funding for a lot more than just us. There's way too many targets for any one company to be able to absorb. So, you know, I think that, is, well, an opportunity and a challenge.

    Yeah.

  23. Jessica Sacher

    Yeah, oh, that's such a fascinating perspective.

  24. Joe Campbell

    So one of the things you didn't talk about in that was endpoints, and one of the things I think I feel that you guys have done really well, and I've been lucky enough to hear some of these discussions is how you go about figuring out the exact endpoints. ’Cause I think that's another point where people can really screw up their clinical trials is by having unrealistic endpoints. Or anyway, you wanna talk about how you guys go about thinking about endpoints?

  25. Paul Garofolo

    Yeah, I mean, I think we start with our secret weapon, which is Dr. Kim. Paul Kim has 30 years in industry developing drugs. Background in places like Eli Lilly and Amgen and others. Paul is, I think, quite familiar with how to best manage endpoints to the phase, and so the earlier the phase, obviously, the least amount of rigor from an efficacy standpoint, with maximum amount of rigor towards safety and tolerability is, I think, the way that people would normally go if they're trialists.

    Leaving the difficult, maybe microbiological, endpoints to exploratory instead of primary or secondary for at least as long as you can. You know, I think we also, I think, have been quite unique in trying our best to not guess at a dose, trying to figure out duration and volume of the… So the dosing regimen, as it's tied to your titer, is really important to get your exposure right.

    And this is very difficult. But I mean, maybe this goes back to some of the other trialist comments. But, you know, if you can get simple PK plus tolerability, and those can be your primary and secondary endpoints, and you put microbiological cure as an exploratory endpoint for a phase 1b type of structure, it’ll be maybe harder to go get 100 million

    dollars, after, depending on how you design the trial, or, you know, what type of control arm you may or may not have or could afford. But I think you're trying to make sure you get the drug where it needs to be. And I think if you're relying on the lytic cycle, you also want to make sure that your initial rounds of infectivity are adsorbing, which would be measured in later time point amplification, insights.

    And so, you know, PK/PD is how drugs work, and I think paying very, very special attention to PK/PD in early stages till you get it right. You really shouldn't progress, because your chances of failure are pretty high. You could have the right drug in the wrong quantity at the wrong time points, and the right drug would fail. You could have a mediocre drug where you perfected the exposure and it might work.

    So which is best? The latter's best, ’cause the latter progresses, the former stops, so it's like, your endpoints are tough. It's not a one-person game, right? It's somewhat of a negotiation with the FDA. You know, you have to follow the guidelines and you have to be able to gain their alignment on the protocol. And you know, not just your endpoints, but your enrollment criteria and how all those things, you know, mix and match.

  26. Jessica Sacher

    Yeah, no, this is super interesting. I feel like we should click in a little bit more to this, kind of like the PK side. And also when you have the approach of having thousands of phages and then down-selecting from there. And I wonder, have you found that there's innate properties of phages themselves that make them more likely to have a good PK profile?

    Like they just handle the serum better or whatever? Or do you have more of a lever in the formulation of the phage and things that are like, not phage-specific?

  27. Paul Garofolo

    I mean, I don't think we know anything that's secret in that arena. I mean, maybe we do. We get pretty high titers compared to most. I think it's not so much an individual phage, in our opinion, as the overlap of phage. And in fairness, we suspect—we don't know. We won't know till we flip this next set of data where we actually have a large placebo cohort.

    And maybe, okay. We think it's really important to get as close to acute infections as you can, to stay as far away from chronic as you can. As you're trying to prove something out, like PK/PD, chronic bacterial infections, you know, I mean, take CF in lung, I mean, that's a polymicrobial, you know, soup of very colonized. And, you know, multipathogenic strain, species, environment.

    It couldn't be more difficult to get down into the nooks and crannies of the lower respiratory tract. And so which phage do you choose? Maybe the ones that actually have better anti-biofilm characteristics versus, let's say, depth of kill? So your target environment, the organ you're going into, how you're gonna get it there. Like, those are the things, Jessica, that I think when you're picking a phage, you wanna actually look at the grouping of what you have to eat through to get to the pathogen.

    And that's undoubtedly one of the hardest parts. See, we don't need phage therapy for regular routine infections, right? ’Cause we have these less-than-a-penny-per-pill antibiotics, which is problematic. We're only really using phage to go after the nastiest stuff we can find, so it's a really difficult target base. If you don't go after that really nasty stuff, that's obviously a much different regulatory pathway, a much larger patient count, likely superiority designs, those types of things just drive up the costs, which we in this sector have been yet to be able to fundraise.

    Anyway, I’m meandering over like ten different subjects at once. But I think which phage go together has a lot to do with the environment in the body that you’re going up against.

  28. Joe Campbell

    Yeah, I mean, I guess chronic infections, almost by definition, have a degree to which they're persisting, and obviously, persisters are tough to deal with for a variety of reasons.

  29. Paul Garofolo

    Yeah,

  30. Joe Campbell

    I'm gonna go ahead.

  31. Paul Garofolo

    I think, to me, the holy grail is intracellular pathogens. I think if we can use phage therapy to address precision medicine needs for intracellular pathogens, the modality’s here to stay.

  32. Jessica Sacher

    Got it.

  33. Paul Garofolo

    If we can do that. And because that is specifically an area where antibiotics do not work, and likely, one of the greatest problem areas of multidrug-resistant infections. But I think that, we suspect, that can be handled through payloads. It may be different regulatory pathways, but I think, we think it can be handled through payloads. So anyway, sorry, Joe, I didn't mean to stop you from your pivot.

  34. Joe Campbell

    No, no, I mean, I think I was, I don't know what else I was gonna say. Jessica, do you have more questions?

  35. Jessica Sacher

    Oh yeah. Well, I'm just kinda thinking about, I think people a lot of times think biofilm and they don’t think intracellular like, I mean, so we're talking about like, there's biofilm. I think we're in the urinary tract infection context with what you guys are targeting right now, right?

  36. Paul Garofolo

    So I'll give you some interesting data that we've been using. So I think something like 65% of the UTIs in the phase 1b and PK/PD uplift portion of our UTI trial tested positive for adherence and invasive characteristics.

    So it's likely, you know… Would those be under some kind of protected biofilm area? Probably, but are they intracellular pathogens that are inside the bladder wall? Is that where these recurrent infections are coming from? I mean, we've been going to ESCMID for a number of years and I think the general shift in thinking has changed a bit, at least in the years that we've been going to the conference.

    In the early days, the idea was that most UTIs might be being caused by reinfection. MDR hangout spots in the intestinal tract that somehow, through either a fissure or poor hygiene, make their way into the urinary tract. I think we've been on the other side of that argument in that we think it's likely colonized bacteria, that is potentially intracellular bacteria. Either from a previous infection event, that didn't quite go away in full, or potentially, you know, just an injury that was a past injury that you just haven't been able to

    to fully clear. You know, you get a UTI, you get treated with antibiotics. It beats it back a little bit, to the point where you feel better, but doesn't get rid of it. And at some point it begins to shed, bloom, and you got a reinfection event.

  37. Jessica Sacher

    Are there intracellular biofilms? I've never contemplated this.

  38. Paul Garofolo

    I don't know if I would say, well, I'm probably not the right person to ask that, but I don't think we think about it that way.

  39. Jessica Sacher

    Okay.

  40. Paul Garofolo

    I think we think about biofilm areas on top of intracellular pathogens, which are on top of cells that are dying, that are shedding their bacterial loads and new bacteria. That's somehow in there. Like, we typically think of, like a soup, Where it's all in there. And what you want to be able to do is get your exposure right, so you're not just clearing what I kinda call transactional bacteria. So the stuff that's likely causing a problem is the non-transient bacteria. That's the stuff that's probably causing a problem, the stuff that doesn't go away. And that, there's…

    I guess we know a lot about this from all of the Crohn's work we've been working on for years. So our theory of one of the causal factors of Crohn's is that intracellular, pathogens are what your body's immune system is actually attacking. And they, are surrounding the lesion areas that Crohn's patients get in their intestinal tracts, and they just get worse and worse, right?

    Some E. coli… Everybody's got E. coli in their guts. Not sure why some patients have that build up, become adherent, not exactly sure how adherence leads to invasion. But, you know, your end result is probably transient, adhesive, and adherent-invasive E. coli that's in your wound areas. And if you massively debulk that bacteria, do you get a corresponding decrease in the immune system's attack? And that, theoretically, is curative, not suppressive, which would be…

    That's why I go back to: I think intracellular pathogens are the holy grail for the field.

    If phage can clear intracellular pathogens where antibiotics cannot, we have a new field of medicine.

  41. Jessica Sacher

    Fascinating. Yeah.

  42. Paul Garofolo

    And dealing with pathogens is maybe the tip of the iceberg, because inflammation in the body, in theory, is the cause behind a substantial amount of chronic disease, for which we in society use suppressive technologies, so immunosuppressants for everything from psoriasis to Crohn's and colitis, right? I mean, you're not actually curing anything, you're just telling your body not to attack yourself. And then, I mean, probably preaching to the choir.

    But I think this is one of the, like, dirty secrets of our industry: we're not really hunting for many cures, although it's changing, certainly, gene therapy's been making, you know, huge strides. Definitely, we've got to get our delivery vectors right on that front, but, you know, going after genetic disease, great. But I think, without question, I think bacteria in the body is certainly causing inflammation.

    Joints, you know, I mean, intestinal tract, you know. And in theory, if we can precisely get the bacteria out that's driving the inflammation, we're gonna see a lot healthier society.

  43. Jessica Sacher

    This is a really great angle because a lot of our audience, I feel, is on the phage research side. And I think they wanna know, like, what's the most important research that they could actually do that would move the needle? In our podcast, we really wanna talk about, like, what's stopping phage from being in the clinic? And so I'm glad that we kind of are landing on this like one kind of concept of our phages

    kill great in liquid culture, whatever, LB broth, but they actually need to get not only through biofilm, but into eukaryotic cells and do their killing there. Like, I don't think that that's talked about much in the phage field as the holy grail.

  44. Paul Garofolo

    Yeah, and I don't.

    Yeah, I don't think a wild-type phage biologically can get into an intracellular path… I mean, Joe, you probably know this better than I do. What we're assuming is that the payloads can get to either a happier and healthier macrophage environment, so that macrophages that should be doing their jobs actually do their jobs. And/or straight delivery of maybe some peptides that do the job for you, and get to those pathogens behind the cellular wall, but that to me, that that's the power of not just the payloads, but the phage cocktails and that We didn't really touch much on that, but I think individual phage that eventually hit, you know, a more rapid resistance profile than what you would want for anything other than personalized medicine. I think we have to try to, if we want large-scale investment into the space, I think we have to be thinking about large-scale commercial drugs to attract that investment.

    And it's hard to see how personalized phage therapy, I mean, it's super important to advance, so I don't wanna say the wrong thing, but I don't think we're attracting, large-scale corporate strategic investment through that form of personalized medicine. And so, cocktails are important, and the payloads that go into those cocktails are equally, if not more important. And I think that, you know, I'll give you a great example of an idea we had from something that was rejected. Not that long ago, but it was a really good idea.

    You know, do tumors, cancerous tumors, have a specific microbiome profile, and can you find phage that can amp off that microbiome profile to deliver a toxic payload that would kill that tumor in place? Could you do that? Could you use phage to do that? I don't think you're getting the easy clinical development pathway that the FDA is saying is available to phage therapy today for that.

    But could you do it? Could you deliver a drug that only amped its payload at the place you need it in the body to eat away a tumor? We think you can. It's tricky,

  45. Jessica Sacher

    I heard about this field of work a couple years back and I wondered, did the whole tumor microbiome field debunk that? Or is that still a thing that there is a tumor microbiome? That part I'm hazy on. Hm.

  46. Paul Garofolo

    So I think microbiome was a field that actually got that massive amount of investment. And then the initial waves of clinical results failed out and/or were mediocre, and it cooled the whole space. But I mean, I think it's important, especially for people that are in the phage research field, to understand the dynamics of that microbiome environment surge. So really, the first-generation, broad-spectrum, sort of fecal-transplant-oriented additive microbe approaches got billions of dollars, just flat out billions of dollars.

    And, you know, when you really think about, like, okay, you're gonna add in copious amounts of a bacterium and hope that it adheres, that invades, why would you add? ’Cause it's easy, that's why you add. Why do you go after cystic fibrosis lung infections if you're in the phage space? ’Cause the CF Foundation gave you five million bucks, so you ha… Like, you know what? But the microbiome space, I think, is just basically collapsed under its own early-stage quick-win, philosophies, I guess, is the easiest way to say it. And the thing that I think is important in that is that I think the microbiome is quite real and I think subtractive prior to additive joint therapies are likely the future of medicine. Carve out a niche,

    get out what you want out and then put something back in there that you want to adhere, to maintain. Don't just drink the maintain every day, assuming that that the bad is gonna somehow be outcompeted. I don't know, no one knows, but I don't think that that theory of add-only works. But

  47. Joe Campbell

    But I guess it's worked fairly well for C. diff,

  48. Paul Garofolo

    So, well, we all have C. diff, right?

  49. Joe Campbell

    Right?

  50. Paul Garofolo

    So C. diff in its base form is there, which might not be that far, Joe, from other things that we wanna have come out. But I think in that particular case of basically adding in a bunch that essentially competes with the C. diff bloom, you're doing that concomitantly with massive amounts of vancomycin, so you had to subtract what was in there to make…

    In fact, all microbiome therapies typically have a front runner of antibiotics. Most gene therapies have front runners of antibiotics that blow out your microbiome right before you dose somebody with a multi-hundred-dollar drug, which is interesting in and of itself, but anyway, we digress a little bit. I just think it's important for people in the phage space to not give up hope on the microbiome.

  51. Jessica Sacher

    Yeah, that's super interesting.

  52. Paul Garofolo

    I think the microbiome is very, very important. And the idea when I first started ten years ago, the idea of trying to understand the microbiome, just the fact that there were trillions of cells in the human body and different for each person, just the math of that was very intimidating to people. Do you think we should be as intimidated now with AI? Is anybody that intimidated now?

  53. Jessica Sacher

    Hm.

  54. Paul Garofolo

    The money's gone. That's the interesting thing. Was it timed right? ’Cause the microbiome is seemingly like a ripe AI problem

  55. Jessica Sacher

    Yeah, totally.

  56. Paul Garofolo

    from my perspective, which is

  57. Joe Campbell

    Yeah,

  58. Paul Garofolo

    another really cool way to look at, ’cause there's the phageome goes with the microbiome. Are they not the same thing?

  59. Joe Campbell

    You know, I'm sure there's other people who've done this. But there's a friend of mine who's at the University of Oregon, Karen Guillemin, and she's done… I mean, she works on zebrafish so you can do a lot of things with the microbiome. And she has a, you know, a modeling collaborator. And they, at least when I talked to them five or ten years ago, they were doing all this stuff where they were introducing into gnotobiotic fish, like, specific microbiomes.

    And like, predicting what was gonna happen and then seeing what the answer was.

  60. Paul Garofolo

    Yeah,

  61. Joe Campbell

    And that, you know, like some of that data, you know, going back and looking at it and mining it with AI. I mean, obviously fish aren't exactly people, but they do have a very similar, you know, immune system and a lot of similarities.

  62. Paul Garofolo

    Yeah, well, it's also difficult. The microbiome's also really difficult, because I think most is studied from, you know, basically stool samples or whatever you excrete, right?

  63. Joe Campbell

    right,

  64. Paul Garofolo

    And I think that that's at best what might be shedding or is transient, which is unlikely to be the problem. Well, the shedding is if you can get it in a… But since we kinda do, well, in this particular sample, what are your greatest masses of different types of bacteria to determine what's in there, not sort of everything that’s in there?

    You really have to get in there and do some biopsies and understand the biopsy outcome from certain problem areas, like, think of lesions for a Crohn's patient. Like, can you get actual tissue that's close to… Which is its own trialistic problems? But that, I think, is where we're going. I think understanding tissue and the surrounding microbiome and phageome environment at that point of problem, like, that I think is a math challenge we can handle now.

    And so, like with time and data, I think you'll have a whole new class of drugs, that spawn up out of that. And I would just encourage people in the phage space to stay after it, because we're likely the ones that'll be there first. We may not stay, but we'll likely be there first.

  65. Jessica Sacher

    Yeah,

  66. Joe Campbell

    So this has been great. And we're getting close to the end of the hour, so we should probably give you our sort of final wrap-up questions. And you've probably touched on some of these things, but you know what of these things? You've talked about a lot of future-looking things. But what's sort of realistic in five years, in 15 years? And what do you think are the biggest barriers to keeping you, keeping Locus and other people from getting there?

  67. Paul Garofolo

    Yeah, well, what we're finding on the Crohn's side, for sure, is patience. The ability to get sites and KOLs and PIs to sign up for trials in light of the just massive amounts of billions of dollars going into research in that space, like finding patients for things that are nonpathogenic, that's gonna be very difficult. And I think it's gonna need to be more in that 15-year bucket, Joe, than that five.

    And that it's just gonna take time to be able to break that open and get the PI attention. I think, infectious disease and pathogenic threats, and really understanding where antibiotics are not going to work and how to push what we think are engineered phage cocktails into those gaps. That's the next five years for us. And so we've got, you know, our lead BARDA program for UTIs.

    Fairly hot off the press. But we now have, a Pseudomonas asset advancing with the NIH and the NIAID division for hospital-acquired pneumonia, and we have a blepharitis indication for staph advancing with Viatris. And so three different body parts, all MDR infection sites, three different sets of payloads, and three different routes of administration. So you're trying to figure out in the next five years, how do you get the right exposure of an engineered drug product to the site of infection to clear it?

    And how do you work concomitantly with antibiotics to make sure those infections never come back? That, I think, opens the field. So the next five years is proving that commercial-grade products will work and hopefully drive a profitable company. The next 15 years, I think, is anti-inflammatory chronic treatments that span across into, you know, human genes. And then we get into things that, probably nobody's thinking about right now.

    That's what I think the future's got.

  68. Jessica Sacher

    Awesome. I think that tie to the inflammation field is, yeah, such an interesting one to unlock and, like, blast it all the way open. ’Cause I feel like when phage gets lumped in as like antibiotic replacement, it's like a tiny market. And everybody wants to… At least, I was under the impression that that's kind of why phage companies haven't raised much money is because that's not an attractive enough, big enough market.

  69. Paul Garofolo

    I think it's actually infectious disease and the MDR. If you label the things correctly, I think it's a pretty big market.

  70. Jessica Sacher

    Okay.

  71. Paul Garofolo

    I don't know if the pricing of those drugs, I don't think that the economics of it can handle the prices that have been coming.

    And I don't mean for phage, I mean for other MDR treatments. And so even on the small-molecule side, certainly the large-molecule side, you start getting into $25,000, $30,000, $35,000 for a particular treatment. You know, you're gonna get the “keep behind glass, break when finally necessary”.

    Like, if you wanna get into dosing millions of patients, you gotta get a price point somewhere that enables, you know, the hospitals to put that drug into a non break glass when needed scenario. And I do think, I actually think, going to the phage side of things, I think phage has the COGS potential to get a priced product that could be concomitant therapy that could break back open millions of patients.

    And that the financial dynamics on that for a drug that's priced anywhere from $1,500 to $2,500 or something. You know, maybe the cost of an iPhone, that kind of thing, I think is possible with phage. So it's unlike any other large molecule in its production capacity, it's quite contagious, as most researchers would know, and so making it is, it's interesting, but definitely doesn't have the same cost dynamics as other large molecules.

    So it's a it's an advantage if you can figure out how to harness it.

  72. Jessica Sacher

    Yeah, okay. Well, that's very encouraging. And so your investors must feel this way, at least to some degree. And it's not all doom and gloom on that side, that antibiotics is a broken market and there can never be a new one.

  73. Paul Garofolo

    We don't think that at all, actually. I think there's a timing element of this. I mean, I do think antibiotic resistance is growing, and in some areas exponentially, that'll continue to grow. And I think you know, it's possible to get in front of it financially. It's just a matter of actually kind of pricing things properly to break it open. So we'll see where it goes.

  74. Jessica Sacher

    Yeah, thank you so much.

  75. Joe Campbell

    I just came up with one last thought, and I know, Jessica, if I need to wrap this up. But have you guys thought about VAP? And like, giving people who are on ventilators for a long time, phages prophylactically? I mean, I think that might be a really hard business market, but if you can incur, I mean, hospitals might, I don't know.

  76. Paul Garofolo

    Well, so we are thinking about VAP, because with the HAP indication, I think 20 to 25% of HAP patients advance to VAP. And we are thinking about the physical device components of the ventilator and the tubes and what that means and how we would get in front of it. We have thought about prophylactic products, Joe, and I think they're definitely on that price spectrum.

    The lower you can get the price, the more you can probably get the pickup. In that, I think there's certainly some… I'll tell you, an area where we think about it all the time is colorectal cancer, because the sort of environment of E. coli and Bacteroides, and you know, all kinds of other crap that's in there, that is a long-range exposure, issue that people believe long-range exposure to those bacteria creates the environment that's right for colorectal cancer to evolve.

    But a long-range prophylactic, especially if you're genetically predisposed to colorectal cancer, if the price of that was correct, we probably could pull it off. It's just a very difficult trial, it's a very long, very expensive trial to get there, but then you'd have a dominant market position. So I think the way we look at the commercial aspects of this, or at least, I'm sure you've heard this one.

    But I mean, people have always looked at us with like four eyeballs. Like, why are you going after UTIs? Why didn't you go after the? The purpose of UTIs is this: millions of patients have recurrent UTIs, and the suspected cause, or one of the suspected causes, is MDR. So we have this beautiful balance between commercial opportunity and regulatory help to advance and get there with some reasonable amount of cost.

    And so, you know, we look at all the things we've built from a platform perspective and think about, well, how many drugs can come off this platform? The first one, you know, it matters a lot, but what matters is the data. It's not necessarily the full commercial, you know, opportunity, by any stretch, honestly. And then you can look at infectious disease as a stepping stone into things like immunology, and immunology is a stepping stone into oncology, and oncology is a stepping stone into neurology.

    And how many of these different areas could have precision microbiome that is eventually part of our mainstream medical treatment? I mean, do you think a hundred years from now somebody's gonna be balancing your microbiome to optimize your longevity? ’Cause that's what you're talking about. I'd say, yes. So we're between now and 100 years from now, and we'll all be dead. But, you know, from here to there, how do we break through?

  77. Joe Campbell

    We blew way past our five and fifteen years here.

  78. Jessica Sacher

    you got 100, we gotta bring that in. Yeah.

  79. Paul Garofolo

    Right?

  80. Joe Campbell

    All right.

  81. Jessica Sacher

    Awesome, thank you.

  82. Joe Campbell

    Well, thanks a lot, Paul. This has been great.

  83. Paul Garofolo

    Sure.

  84. Joe Campbell

    I don't know if Jessica has another question or not,

  85. Jessica Sacher

    I know, I'm good to close this out. Thank you so much.

    what do you need help with from the phage world, or what would you like to direct people to that you're excited about? Or anything that we can tell them, leave them with?

  86. Paul Garofolo

    I mean, I think we're always looking for talent. You know, and primarily our labs and manufacturing are based in North Carolina, so that's always interesting.

  87. Jessica Sacher

    That's an awesome skill.

  88. Paul Garofolo

    We hear a lot from folks from places that maybe don't wanna come to North Carolina, but for those that want to come to North Carolina, love to be able to network, and love to be able to actually collaborate with others as well. For what it's worth, we love payloads. And so if you're out there and you're thinking about things to work on some payloads and maybe you can sell your payloads, to Locus or anybody else.

    And then I think, just as a general word of encouragement, I mean, I do think the U.S. government specifically has a pretty solid track record of making, large investments to try to help people advance platforms that could change things dramatically. And I, you know, I would just encourage as much government interaction as you can get. We've found the FDA to be incredibly partner-oriented.

    I've never seen the FDA so collaborative as they are in this space. It's really cool to see. It's hard, but it's cool to see. I've never really, until this job, gone deep in with Health and Human Services in so many areas. Between the NIH and between BARDA and the NIH has been great. And I think the Department of Defense has, obviously had a well-worn track record investing in this stuff and that those dollars matter.

    So if I was at one of the bigger labs, I'd be trying to chase some of those ’cause the more funding scale you can book to your endeavors, the better the assets that come out. So I think it's a very promising field. I think we've been around for a long time and I think we have, a bevy of mediocre to poor data that now we have to weed through.

    But for those that are maybe a little bit longer-range in their vision, I don't think you have a safer delivery vector to get something into the human body that's better than phage. It can carry a mass that other delivery vectors cannot, and it does not infect human cells. And so what can you do with a phage?

    That's a really exciting question.

  89. Jessica Sacher

    Yeah, cool, awesome, great. Well, leave it at that. Thanks so much, Paul.

  90. Paul Garofolo

    Yeah, absolutely.

  91. Jessica Sacher

    See you.